1,721,269 research outputs found
Critical evaluation of urodynamic studies in assessment and treatment of men with lower urinary tract symptoms
Full text linkContains fulltext :
18983.pdf (Publisher’s version ) (Open Access)KUN, 08 juni 2001Promotor : Debruyne, F.M.J.136 p
Cell Adhesion Molecules in Bladder and Prostate Cancer.
No full textContains fulltext :
59193.pdf (Publisher’s version ) (Open Access)KUN, 22 maart 2004Promotores : Schalken, J.A., Debruyne, F.M.J.89 p
Micturition varibles in the assessment and treatment of patients with lower urinary tract symptoms
No full textItem does not contain fulltextKUN, 21 mei 1997Promotor : Debruyne, F.M.J. Co-promotor : Rosette, J.J.M.H.C. de la251 p
Expression and significance of cadherin-catenin complex in Renal Cell Carcinoma.
Full text linkContains fulltext :
32075_expransio.pdf (Publisher’s version ) (Open Access)RU Radboud Universiteit Nijmegen, 17 december 2007Promotores : Debruyne, F.M.J., Schalken, J.A. Co-promotor : Oosterwijk, E.101 p
Models for Prostate Cancer. Molecular Characterization and Critical Appraisal of Human Prostate Carcinoma Cell Lines.
No full textContains fulltext :
58826.pdf (Publisher’s version ) (Open Access)KUN, 22 maart 2004Promotores : Schalken, J.A., Debruyne, F.M.J. Co-promotor : Bussemakers, M.J.G.192 p
Selective detrusor activation by electrical stimulation of the sacral nerve roots
No full textItem does not contain fulltextUrologie, 23 september 1996Promotores : Debruyne, F.M.J., Oosterom, A. van, Wijkstra, H., Kerrebroeck, P.E.V.A. van132 p
PTNS: a new treatment option for lower urinary tract dysfunction.
Full text linkContains fulltext :
51953.pdf (Publisher’s version ) (Open Access)Nearly one out of two Dutch married women experiences urine loss. Overactivity of the bladder can cause urine loss and frequent micturition. At the urology department of the UMC Nijmegen, Posterior Tibial Nerve Stimulation or PTNS to treat overactive bladder complaints was investigated. Also patients with voiding dysfunction were examined. 90 patients with overactive bladder complaints and 39 patients with voiding dysfunction were enrolled in the study. All patients received 12 weekly sessions in which a needle was placed three fingerbreadths above the medial ankle and connected to a low voltage stimulator for 30 minutes. 60-64% of the participants considered the treatment as successful and demanded maintenance therapy. Patients presented with less urine loss and less urinary frequency. 38% was even considered as continent. Urodynamic investigation confirmed increment of bladder capacity, a larger volume at which desire to void appears and more efficient bladder emptying. Quality of life parameters improved. No mayor side effects were seen. PTNS is minimally invasive treatment without serious side effects. Unfortunately a long term maintenance schedule is needed; therefore more investigation concerning the implantable stimulator is warrantedRU Radboud Universiteit Nijmegen, 17 september 2007Promotores : Bemelmans, B.L.H., Debruyne, F.M.J. Co-promotor : Heesakkers, P.F.A.139 p
Tibial nerve stimulation in the treatment of refractory overactive bladder syndrome.
Full text linkContains fulltext :
51062.pdf (Publisher’s version ) (Open Access)Overactive bladder syndrome (OAB) is a common dysfunction of the lower urinary tract and has a large impact on the patient's quality of life. Percutaneous tibial nerve stimulation (PTNS) has been introduced as an alternative neuromodulative treatment. This thesis discusses the basic science and applications of tibial nerve stimulation in the treatment of refractory OAB. Though much research has been performed the mechanism of action of neuromodulation is still unclear. It is most likely a combination of the different suggested modes of action, involving the neuroaxis at different levels. The female cat model is suitable to investigate the effect of PTNS. In this thesis it demonstrates that PTNS modulates the micturition reflex reversibly. Moreover, the sacral plexus seems to be involved in the modulation process. Still, randomized studies in patients are needed to obtain irrefutable proof that neuromodulation is effective. It is generally assumed that the improved quality of life in PTNS treated patients is due to improved voiding parameters. The present thesis confirms this and shows that patients must have a reduction of at least 2 used pads before their quality of life improves. Maintenance treatment is performed after successful PTNS treatment, usually every 2-3 weeks. The thesis demonstrates that maintenance therapy is necessary in successfully treated patients. Furthermore, it shows that successful therapy can be reproduced. Maintenance therapy is demanding for both patient and hospital facilities, since each patient put on a maintenance schedule will visit the outpatients' department at least 20 to 30 times per annum. A subcutaneous implant has been developed to enable self-treatment at home. The thesis demonstrates that implant driven tibial nerve stimulation is possible and safe during 1-year follow up.RU Radboud Universiteit Nijmegen, 11 oktober 2006Promotores : Debruyne, F.M.J., Bemelmans, B.L.H. Co-promotor : Heesakkers, J.P.F.A.100 p
Specific immunotherapy for renal cell carcinoma.
Full text linkContains fulltext :
50137.pdf (Publisher’s version ) (Open Access)Despite the fact that evaluation of cytokine-based therapies for mRCC shows that a subset of patients react favourable to immunotherapy, significant side effects do occur. With the increased knowledge of tumor-immunology, the recognition of immunogenic tumor proteins and antibodies, new treatment options with increased specificity and subsequently less side-effects are of interest. In this thesis several studies have been performed to evaluate these new treatment options. Chapter 2 discusses the need for a staging sytem that adequately discriminates patients with RCC into prognostic groups in order to provide improved counseling, follow-up evaluation and identification of high risk patients potentially suitable for adjuvant therapies and clinical trials. This chapter presents a clinical algorithm using 3 well-known prognostic factors that can be used to predict survival and stratify patients undergoing nephrectomy for localized disease into 3 risk groups. External data from 2 outside institutions suggest the validity of this algorithm with a high concordance index. These risk categories can be used in clinical trial design and interpretation as well as in clinical management areas such as surveillance. Chapters 3 & 4 discuss dendritic cell-based immunotherapy. Dendritic cells (DC) are the most potent antigen presenting cells (APC's) of the immune system with the ability to stimulate naive resting T cells to proliferate and differentiate into activated cytotoxic T cells specific against the presented antigen. Two clinical trials were performed evaluating safety and clinical or immunological responses of DC-based vaccines. Chapters 5 & 6 deal with monoclonal antibody-based immunotherapy. Currently, several monoclonal antibodies (mAb) are used in cancer treatment. In RCC the chimeric mAb G250 (WX-G250) has been identified and developed for both therapeutical and diagnostical purposes. Antibody dependent cellular cytotoxicity (ADCC) has been suggested to be the main effector mechanism of WX-G250 and in-vitro data showed that interleukin-2 (IL-2) has the capacity to up-regulate WX-G250 mediated ADCC. This led to the initiation of two successive clinical trials evaluating infusions of WX-G250 as monotherapy and the combination of WX-G250 with a low-dose IL-2 pulsing regimenRU Radboud Universiteit Nijmegen, 27 juni 2006Promotor : Debruyne, F.M.J. Co-promotores : Mulders, P.F.A., Oosterwijk, E.144 p
- …
